Vaccinex announces it will present new data for Phase 1b/2 SIGNAL-AD study

Vaccinex (VCNX) announced that it will present promising new efficacy and safety data for its randomized, double-blind, phase 1b/2 SIGNAL-AD study of pepinemab treatment for Alzheimer’s disease at the Clinical Trials on Alzheimer’s Disease, CTAD, Conference in Madrid, on October 31, 2024. What can we expect to learn from results of this study: Vaccinex scientists discovered and published that Semaphorin 4D is highly upregulated on stressed or damaged neurons during progression of Alzheimer’s Disease; Astrocytes undergo extensive changes in morphology and gene expression when SEMA4D binds to their receptors; The Company’s hypothesis is that treating with pepinemab antibody that binds SEMA4D can block signaling through astrocyte receptors and slow or prevent the damaging consequences of astrocyte activation; Key outcomes of the SIGNAL-AD study include the impact of pepinemab treatment on cognitive decline as well as biomarkers of disease progression.